- Previous Close
1.280 - Open
1.280 - Bid 1.210 x --
- Ask 1.250 x --
- Day's Range
1.170 - 1.280 - 52 Week Range
0.720 - 13.180 - Volume
1,597,500 - Avg. Volume
814,622 - Market Cap (intraday)
612.578M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.060 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; in phase III clinical trial to treat type 2 diabetes mellitus; is in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease. The company was founded in 2011 and is headquartered in Shenzhen, China.
www.hightidetx.comRecent News: 2511.HK
View MorePerformance Overview: 2511.HK
Trailing total returns as of 12/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2511.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2511.HK
View MoreValuation Measures
Market Cap
643.46M
Enterprise Value
68.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.47%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-600.51M
Diluted EPS (ttm)
-2.060
Balance Sheet and Cash Flow
Total Cash (mrq)
563.44M
Total Debt/Equity (mrq)
4.21%
Levered Free Cash Flow (ttm)
-218.86M